Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children.

Raqib R, Sarker P, Zaman K, Alam NH, Wierzba TF, Maier N, Talukder K, Baqui AH, Suvarnapunya AE, Qadri F, Walker RI, Fix A, Venkatesan MM.

Hum Vaccin Immunother. 2019;15(6):1326-1337. doi: 10.1080/21645515.2019.1575165. Epub 2019 Mar 19.

PMID:
30794051
2.

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.

Frenck RW Jr, Baqar S, Alexander W, Dickey M, McNeal M, El-Khorazaty J, Baughman H, Hoeper A, Barnoy S, Suvarnapunya AE, Kaminski RW, Venkatesan MM.

Vaccine. 2018 Aug 6;36(32 Pt B):4880-4889. doi: 10.1016/j.vaccine.2018.06.063. Epub 2018 Jul 2.

PMID:
30037478
3.

The Galleria mellonella larvae as an in vivo model for evaluation of Shigella virulence.

Barnoy S, Gancz H, Zhu Y, Honnold CL, Zurawski DV, Venkatesan MM.

Gut Microbes. 2017 Jul 4;8(4):335-350. doi: 10.1080/19490976.2017.1293225. Epub 2017 Feb 13.

4.

Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.

Pitisuttithum P, Islam D, Chamnanchanunt S, Ruamsap N, Khantapura P, Kaewkungwal J, Kittitrakul C, Luvira V, Dhitavat J, Venkatesan MM, Mason CJ, Bodhidatta L.

Clin Vaccine Immunol. 2016 Jul 5;23(7):564-75. doi: 10.1128/CVI.00665-15. Print 2016 Jul.

5.

A study of different buffers to maximize viability of an oral Shigella vaccine.

Chandrasekaran L, Lal M, Van De Verg LL, Venkatesan MM.

Vaccine. 2015 Nov 17;33(46):6156-60. doi: 10.1016/j.vaccine.2015.09.063. Epub 2015 Oct 1.

PMID:
26428454
6.

A novel protein-based subunit Shigella vaccine candidate.

Venkatesan MM.

Immunol Cell Biol. 2015 Aug;93(7):603-4. doi: 10.1038/icb.2015.56. Epub 2015 Jun 9. No abstract available.

PMID:
26054727
7.

Combination vaccines against diarrheal diseases.

Venkatesan MM, Van de Verg LL.

Hum Vaccin Immunother. 2015;11(6):1434-48. doi: 10.4161/21645515.2014.986984. Review.

8.

The genome of Shigella dysenteriae strain Sd1617 comparison to representative strains in evaluating pathogenesis.

Vongsawan AA, Kapatral V, Vaisvil B, Burd H, Serichantalergs O, Venkatesan MM, Mason CJ.

FEMS Microbiol Lett. 2015 Mar;362(5). pii: fnv011. doi: 10.1093/femsle/fnv011. Epub 2015 Jan 28.

9.

Editorial commentary: a Shigella vaccine against prevalent serotypes.

Van de Verg LL, Venkatesan MM.

Clin Infect Dis. 2014 Oct;59(7):942-3. doi: 10.1093/cid/ciu471. Epub 2014 Jun 23. No abstract available.

PMID:
24958237
10.

Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.

Gregory M, Kaminski RW, Lugo-Roman LA, Galvez Carrillo H, Tilley DH, Baldeviano C, Simons MP, Reynolds ND, Ranallo RT, Suvarnapunya AE, Venkatesan MM, Oaks EV.

Infect Immun. 2014 May;82(5):2027-36. doi: 10.1128/IAI.01665-13. Epub 2014 Mar 4.

11.

Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes.

Ranallo RT, Kaminski R, Baqar S, Dutta M, Lugo-Roman LA, Boren T, Barnoy S, Venkatesan MM.

Vaccine. 2014 Mar 26;32(15):1754-60. doi: 10.1016/j.vaccine.2013.12.068. Epub 2014 Feb 9.

PMID:
24522159
12.

Evaluation of an intragastric challenge model for Shigella dysenteriae 1 in rhesus monkeys (Macaca mulatta) for the pre-clinical assessment of Shigella vaccine formulations.

Islam D, Ruamsap N, Khantapura P, Aksomboon A, Srijan A, Wongstitwilairoong B, Bodhidatta L, Gettayacamin M, Venkatesan MM, Mason CJ.

APMIS. 2014 Jun;122(6):463-75. doi: 10.1111/apm.12168. Epub 2013 Sep 13.

13.

Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria.

Bergmann-Leitner ES, Hosie H, Trichilo J, Deriso E, Ranallo RT, Alefantis T, Savranskaya T, Grewal P, Ockenhouse CF, Venkatesan MM, Delvecchio VG, Angov E.

Front Immunol. 2013 Jul 4;4:176. doi: 10.3389/fimmu.2013.00176. eCollection 2013.

14.

Evaluation of virulent and live Shigella sonnei vaccine candidates in a gnotobiotic piglet model.

Jeong KI, Venkatesan MM, Barnoy S, Tzipori S.

Vaccine. 2013 Aug 20;31(37):4039-46. doi: 10.1016/j.vaccine.2013.04.076. Epub 2013 May 15.

PMID:
23684833
15.

Establishment of a Shigella sonnei human challenge model in Thailand.

Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang KT, Islam D, Bussaratid V, Venkatesan MM, Hale TL, Mason CJ.

Vaccine. 2012 Nov 19;30(49):7040-5. doi: 10.1016/j.vaccine.2012.09.061. Epub 2012 Oct 12.

16.

Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.

Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, Venkatesan MM.

Vaccine. 2012 Jul 20;30(34):5159-71. doi: 10.1016/j.vaccine.2012.05.003. Epub 2012 May 30.

PMID:
22658966
17.

Further characterization of Shigella sonnei live vaccine candidates WRSs2 and WRSs3-plasmid composition, invasion assays and Sereny reactions.

Bedford L, Fonseka S, Boren T, Ranallo RT, Suvarnapunya AE, Lee JE, Barnoy S, Venkatesan MM.

Gut Microbes. 2011 Jul-Aug;2(4):244-51. doi: 10.4161/gmic.2.4.17042. Epub 2011 Jul 1. No abstract available.

PMID:
21983066
18.

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens.

Feller AJ, McKenzie R, Taylor DN, Woods CC, Grahek SL, Islam D, Venkatesan MM, Hale TL, Bourgeois AL.

Vaccine. 2011 Nov 3;29(47):8487-9. doi: 10.1016/j.vaccine.2011.09.030. Epub 2011 Sep 20.

19.

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM.

Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17.

PMID:
21596086
20.

Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM.

Vaccine. 2010 Feb 10;28(6):1642-54. doi: 10.1016/j.vaccine.2009.11.001. Epub 2009 Nov 20.

21.

Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Ranallo RT, Kaminski RW, George T, Kordis AA, Chen Q, Szabo K, Venkatesan MM.

Infect Immun. 2010 Jan;78(1):400-12. doi: 10.1128/IAI.00533-09. Epub 2009 Nov 2.

22.

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

Gaston JS, Inman RD, Ryan ET, Venkatesan MM, Barry EM, Hale TL, Bourgeois AL, Walker RI.

Vaccine. 2009 Sep 4;27(40):5432-4. doi: 10.1016/j.vaccine.2009.06.107. Epub 2009 Jul 28.

PMID:
19643213
23.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
24.

Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta).

Collins TA, Barnoy S, Baqar S, Ranallo RT, Nemelka KW, Venkatesan MM.

Comp Med. 2008 Feb;58(1):88-94.

25.

Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC.

Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, Duncan JA, Barnoy S, Venkatesan MM, Flavell RA, Deshmukh M, Hoffman HM, Ting JP.

Cell Host Microbe. 2007 Sep 13;2(3):147-59.

26.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78. Epub 2006 Dec 20.

PMID:
17229494
27.

Live-attenuated Shigella vaccines.

Venkatesan MM, Ranallo RT.

Expert Rev Vaccines. 2006 Oct;5(5):669-86. Review.

PMID:
17181440
28.

Developing live Shigella vaccines using lambda Red recombineering.

Ranallo RT, Barnoy S, Thakkar S, Urick T, Venkatesan MM.

FEMS Immunol Med Microbiol. 2006 Aug;47(3):462-9.

29.

An AFLP-based database of Shigella flexneri and Shigella sonnei isolates and its use for the identification of untypable Shigella strains.

Sirisriro T, Sethabutr O, Mason C, Talukder KA, Venkatesan MM.

J Microbiol Methods. 2006 Dec;67(3):487-95. Epub 2006 Jul 11.

PMID:
16837089
31.

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D, Wolf MK, Venkatesan MM, Hale TL.

Infect Immun. 2005 Dec;73(12):8027-32.

32.

Shigella and Salmonella: death as a means of survival.

Haimovich B, Venkatesan MM.

Microbes Infect. 2006 Feb;8(2):568-77. Epub 2005 Oct 7. Review.

PMID:
16297650
33.
35.

Molecular epidemiology of Shigella flexneri in a diarrhoea-endemic area of Lima, Peru.

Fernandez-Prada CM, Venkatesan MM, Franco AA, Lanata CF, Sack RB, Hartman AB, Spira W.

Epidemiol Infect. 2004 Apr;132(2):303-16.

36.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

37.

Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T.

Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR.

Infect Immun. 2003 May;71(5):2775-86. Erratum in: Infect Immun. 2003 Jul;71(7):4223.

38.

Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.

Venkatesan MM, Hartman AB, Newland JW, Ivanova VS, Hale TL, McDonough M, Butterton J.

Infect Immun. 2002 Jun;70(6):2950-8.

39.

Inactivation of DsbA alters the behaviour of Shigella flexneri towards murine and human-derived macrophage-like cells.

Yu J, Oragui EE, Stephens A, Kroll JS, Venkatesan MM.

FEMS Microbiol Lett. 2001 Oct 16;204(1):81-8.

40.

Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri.

Venkatesan MM, Goldberg MB, Rose DJ, Grotbeck EJ, Burland V, Blattner FR.

Infect Immun. 2001 May;69(5):3271-85.

41.

Shigella flexneri IpaH(7.8) facilitates escape of virulent bacteria from the endocytic vacuoles of mouse and human macrophages.

Fernandez-Prada CM, Hoover DL, Tall BD, Hartman AB, Kopelowitz J, Venkatesan MM.

Infect Immun. 2000 Jun;68(6):3608-19.

43.

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL.

Infect Immun. 1999 Jul;67(7):3437-43.

46.
47.

Identification and molecular characterization of a 27 kDa Shigella flexneri invasion plasmid antigen, IpaJ.

Buysse JM, Dunyak DS, Hartman AB, Venkatesan MM.

Microb Pathog. 1997 Dec;23(6):357-69.

PMID:
9441862
48.

Characterization of Shigella type 1 fimbriae: expression, FimA sequence, and phase variation.

Snellings NJ, Tall BD, Venkatesan MM.

Infect Immun. 1997 Jun;65(6):2462-7.

49.
50.

Supplemental Content

Loading ...
Support Center